Bevacizumab versus ranibizumab in age-related macular degeneration

A prospective randomised, double-masked clinical trial comparing bevacizumab to ranibizumab in age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN73359806

Enrollment

125

Registered

2009-04-30

Start date

2007-04-07

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration Eye Diseases Other retinal disorders

Interventions

Intravitreal injection with ranibizumab or bevacizumab based on random allocation. Dosage: Ranibizumab 0.5 mg/0.05 ml, bevacizumab 1.25 mg/0.05 ml Method/frequency: Intraocular injections monthly fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Exudative AMD involving the foveal centre confirmed by intravenous fluorescein angiography 2. Aged greater than 50 years, either sex 3. Ability to provide informed consent

Exclusion criteria

Exclusion criteria: 1. Previous treatment for exudative AMD in the past one year 2. Presence of subretinal haemorrhage that is greater than 50% of the size of the lesion 3. Advanced glaucoma 4. Any co-existing macular disease causing decreased vision 5. Uncontrolled hypertension 6. History of thromboembolic phenomenon 7. Participation in another concurrent ophthalmic trial

Design outcomes

Primary

Measure	Time frame
Visual acuity, measured at 6 months and one year	—

Secondary

Measure	Time frame
1. Central foveal thickness, measured at 6 months and one year 2. Quality of life assessment, measured at one year	—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026